Characterization of multiple driver alterations in acquired resistance to osimertinib in EGFR-mutated lung cancer: implementation of single cell approaches

被引：0
|
作者：
Chen, Jeanne [1 ]
Braye, Floriane [1 ]
Facchinetti, Francesco [1 ]
Lacroix, Ludovic [1 ]
Scoazec, Jean-Yves [1 ]
Tselikas, Lambros [1 ]
Planchard, David [1 ]
Mezquita, Laura [1 ]
Gazzah, Anas [1 ]
Naltet, Charles [1 ]
Lavaud, Pernelle [1 ]
Maillard, Aline [1 ]
Michiels, Stefan [1 ]
Massard, Christophe [1 ]
Olaussen, KenA [1 ]
Andr, Fabrice [1 ]
Vassal, Gilles [1 ]
Soria, Jean-Charles [1 ]
Besse, Benjamin [1 ]
Friboulet, Luc [1 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-1867
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1867
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
    Juliann Chmielecki
    Tony Mok
    Yi-Long Wu
    Ji-Youn Han
    Myung-Ju Ahn
    Suresh S. Ramalingam
    Thomas John
    Isamu Okamoto
    James Chih-Hsin Yang
    Frances A. Shepherd
    Krishna C. Bulusu
    Gianluca Laus
    Barbara Collins
    J. Carl Barrett
    Ryan J. Hartmaier
    Vassiliki Papadimitrakopoulou
    Nature Communications, 14
  • [32] Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?
    Leonetti, Alessandro
    Facchinetti, Francesco
    Tiseo, Marcello
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
  • [33] Targeting non-coding RNAs to overcome osimertinib resistance in EGFR-mutated non-small cell lung cancer
    Zeng, Beilei
    Gan, Kelun
    Yu, Yuanhang
    Hu, Jianping
    Deng, Qiao
    Yin, Chong
    Gao, Xi
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [34] PNEUMONITIS RISK FOLLOWING COMBINED OSIMERTINIB AND THORACIC RADIOTHERAPY IN EGFR-MUTATED NONSMALL CELL LUNG CANCER
    Mak, David Y.
    Nusrat, Humza
    Yan, Michael
    Parmar, Ambika
    Poon, Ian
    Ung, Yee
    Tsao, May
    Warner, Andrew
    Cheung, Patrick
    Louie, Alexander V.
    RADIOTHERAPY AND ONCOLOGY, 2023, 186 : S12 - S12
  • [35] Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study
    Mehlman, Camille
    Cadranel, Jacques
    Rousseau-Bussac, Gaelle
    Lacave, Roger
    Pujals, Anais
    Girard, Nicolas
    Callens, Celine
    Gounant, Valerie
    Theou-Anton, Nathalie
    Friard, Sylvie
    Tredaniel, Jean
    Blons, Helene
    Dujon, Cecile
    Duchemann, Boris
    Schischmanoff, Pierre Olivier
    Chinet, Thierry
    Leprieur, Etienne Giroux
    LUNG CANCER, 2019, 137 : 149 - 156
  • [36] Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer
    Popat, Sanjay
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 192 - 193
  • [37] Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
    Kunimasa, Kei
    Kamada, Risa
    Oka, Toru
    Oboshi, Makiko
    Kimura, Madoka
    Inoue, Takako
    Tamiya, Motohiro
    Nishikawa, Tatsuya
    Yasui, Taku
    Shioyama, Wataru
    Nishino, Kazumi
    Imamura, Fumio
    Kumagai, Toru
    Fujita, Masashi
    JACC: CARDIOONCOLOGY, 2020, 2 (01): : 1 - 10
  • [38] Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer
    Spagnuolo, Alessia
    Gridelli, Cesare
    EXPERT OPINION ON PHARMACOTHERAPY, 2025,
  • [39] Early dose reduction of osimertinib in advanced EGFR-mutated non-small cell lung cancer
    Ferreira, Marion
    Ebia, Matthew I.
    Reckamp, Karen L.
    ANTI-CANCER DRUGS, 2024, 35 (07) : 672 - 679
  • [40] Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer
    Di Marino, Pietro
    Chiapperino, Cosima
    Primavera, Francesca Chiara
    Martino, Maria Teresa
    Brocco, Davide
    Carella, Consiglia
    Grassadonia, Antonino
    Tinari, Nicola
    De Tursi, Michele
    ONCOTARGETS AND THERAPY, 2022, 15 : 407 - 410
12345